GlassScriptPhysician profile
Arturo Homma
NPI 1306841556
$11,883.10
in general payments reported to CMS, 2019-2025
42 companies · $3,185 in 2025
The $3,185 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,187 · 2020: $521 · 2021: $975 · 2022: $1,433 · 2023: $1,704 · 2024: $1,877 · 2025: $3,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,655.61 |
| Education | $110.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,312.61 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,601.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,442.33 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $986.83 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $448.00 | 2019-2024 | Yupelri |
| Abbvie INC. | $413.08 | 2022-2025 | |
| United Therapeutics Corporation | $411.73 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Genzyme Corporation | $391.95 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $383.62 | 2019-2024 | Dupixent |
| Inari Medical, INC. | $315.68 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $315.49 | 2022-2024 | Impella |
| Amgen INC. | $306.89 | 2023-2025 | Tezspire |
| Insmed, INC. | $260.48 | 2022-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $243.48 | 2021-2022 | |
| Philips North America LLC | $212.15 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy, (8874) Incourage |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $205.85 | 2025 | Winrevair |
| Grifols USA, LLC | $176.51 | 2019-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $167.75 | 2019-2023 | |
| Gilead Sciences, INC. | $163.38 | 2019-2024 | Veklury |
| Jazz Pharmaceuticals INC. | $143.01 | 2025 | |
| Pulmonx Corporation | $130.04 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $119.86 | 2020-2025 | |
| Abbott Laboratories | $118.47 | 2020 | |
| Genentech USA, INC. | $106.88 | 2019 | |
| Inspire Medical Systems, INC. | $50.16 | 2024-2025 | Inspire |
| Electromed, INC. | $49.71 | 2025 | Smartvest |
| Chiesi USA, INC. | $42.37 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $39.64 | 2019 | |
| Verona Pharma, INC. | $33.79 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $33.03 | 2022 | |
| Viatris Specialty LLC | $30.75 | 2025 | Yupelri |
| Pfizer INC. | $28.93 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $26.06 | 2019 | |
| Portola Pharmaceuticals, LLC | $24.53 | 2019 | |
| Baxter Healthcare | $23.37 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $22.35 | 2025 | Acthar |
| Advanced Respiratory, INC | $21.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.80 | 2021 | |
| Fisher & Paykel Healthcare INC | $18.53 | 2023 | Fisher & Paykel Healthcare |
| Ani Pharmaceuticals, INC. | $15.14 | 2025 | Purified Cortrophin Gel |
| Itamar Medical INC | $13.48 | 2023 | Watchpatone |
| Melinta Therapeutics, LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Homma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.